ImmunoGen, Inc. Announces Presentations at 2012 ASCO Annual Meeting on Product Candidates with the Company’s TAP Technology
May 16 2012 - 6:30AM
Business Wire
ImmunoGen, Inc. (NASDAQ: IMGN), a biotechnology company that
develops targeted antibody-based anticancer products, today
announced that there will be four presentations at the upcoming
2012 American College of Clinical Oncology (ASCO) Annual Meeting on
compounds that utilize the Company’s Targeted Antibody Payload
(TAP) technology. Of particular note, the findings in the
trastuzumab emtansine EMILIA Phase III trial will be featured
in an ASCO plenary session on June 3, and findings with SAR3419
administered with its Phase II dosing schedule will be reported in
a poster presentation on June 4, 2012. Trastuzumab emtansine and
SAR3419 are in development by Roche and Sanofi, respectively, under
agreements with ImmunoGen.
“ASCO’s decision to feature the EMILIA data in a plenary session
speaks to the significance they attach to the findings,” commented
Daniel Junius, President and CEO. “We developed our TAP technology
to enable the creation of better anticancer therapies, and the data
reported to date with trastuzumab emtansine support that it can
offer meaningful efficacy and tolerability advantages. On June 6
the body of data for trastuzumab emtansine will advance to a new
level with the presentation of the findings from its first Phase
III trial.”
Mr. Junius continued, “There are many other TAP compounds
advancing through both our own product programs and those of our
partners. We’re particularly pleased that Phase I data with SAR3419
administered with its Phase II dosing schedule also will be
reported at ASCO. While trastuzumab emtansine helps demonstrate the
significance of our technology in a solid tumor indication, SAR3419
is well positioned to help demonstrate this in liquid tumor
indications.”
Trastuzumab Emtansine Presentations
- June 2, Breast Cancer - HER2/ER Poster
Discussion Session, Display: 1:15 - 5:15 pm in E450a. Discussion:
4:45 - 5:45 PM in E Hall D2.“Results from a phase Ib study of
trastuzumab emtansine, paclitaxel, and pertuzumab in patients with
HER2-positive metastatic breast cancer previously treated with
trastuzumab.” Abstract #528. Poster Board #18. Presenter: Shanu
Modi, MD.“Cardiac safety in a phase II study of trastuzumab
emtansine following anthracycline-based chemotherapy as adjuvant or
neoadjuvant therapy for early-stage HER2-positive breast cancer.”
Abstract #532. Poster Board #22. Presenter: Chau T. Dang, MD.
- June 3, Plenary Session, in N Hall
B11:45 - 2:00 pm “Primary results from EMILIA, a phase III study of
trastuzumab emtansine versus capecitabine and lapatinib in
HER2-positive locally advanced or metastatic breast cancer
previously treated with trastuzumab and a taxane.” Abstract #LBA1.
Presenter: Kimberly L. Blackwell, MD.2:00 - 2:15 pm Discussion.
Discussant: Louis M. Weiner, MD.
SAR3419 Presentation
- June 4, Lymphoma and Plasma Cell
Disorders General Poster Session, 1:15 - 5:15 pm in S Hall
A2.“Phase I study cohort evaluating an optimized administration
schedule of SAR3419, an anti-CD19 DM4-loaded antibody drug
conjugate, in patients with CD19-positive relapsed/refractory
b-cell non-Hodgkin’s lymphoma (NCT00796731).” Abstract #8057.
Poster Board: #33F. Presenter: Bertrand Coiffier, MD, PhD.
About ImmunoGen, Inc.
ImmunoGen, Inc. develops targeted anticancer therapeutics using
the Company's expertise in tumor biology, monoclonal antibodies,
potent cancer-cell killing agents and engineered linkers. The
Company's TAP technology uses monoclonal antibodies to deliver one
of ImmunoGen's proprietary cancer-cell killing agents specifically
to tumor cells. There are now numerous TAP compounds in clinical
development with a wealth of clinical data reported. ImmunoGen's
collaborative partners include Amgen, Bayer HealthCare, Biotest,
Lilly, Novartis, Roche, and Sanofi. The most advanced compound
using ImmunoGen's TAP technology, trastuzumab emtansine (T-DM1), is
in Phase III testing through the Company's collaboration with
Genentech, a member of the Roche Group. More information about
ImmunoGen can be found at www.immunogen.com.
This press release includes forward-looking statements. For
these statements, ImmunoGen claims the protection of the safe
harbor for forward-looking statements provided by the Private
Securities Litigation Reform Act of 1995. It should be noted that
there are risks and uncertainties related to the development of
novel anticancer products, including trastuzumab emtansine and
SAR3419, including risks related to clinical studies and their
results. A review of these risks can be found in ImmunoGen’s Annual
Report on Form 10-K for the fiscal year ended June 30, 2011 and
other reports filed with the Securities and Exchange
Commission.
ImmunoGen (NASDAQ:IMGN)
Historical Stock Chart
From Jun 2024 to Jul 2024
ImmunoGen (NASDAQ:IMGN)
Historical Stock Chart
From Jul 2023 to Jul 2024